Cingulate (CINGW) Total Non-Current Liabilities (2021 - 2026)
Cingulate's (CINGW) quarterly Total Non-Current Liabilities came in at $968455.0 in Q2 2026, down 56.99% quarter-over-quarter from $2.3 million in Q4 2025.
Analysis
Cingulate (CINGW) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Cingulate (CINGW) has reported Total Non-Current Liabilities for 6 consecutive years, with $968455.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Total Non-Current Liabilities changed N/A year-over-year to $968455.0; the trailing twelve-month figure through Jun 2026 stood at $968455.0 (changed N/A YoY), and the FY2025 full-year result was $2.3 million, down 7.6% from the prior year.
- Total Non-Current Liabilities slipped to $968455.0 in Q2 2026 per CINGW's latest filing, from $2.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $2.4 million in Q4 2024 and bottomed at $33145.0 in Q1 2024.
- Historically, Total Non-Current Liabilities has averaged $834527.8 across 5 years, with a median of $557188.5 in 2022.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities sank 92.16% in 2024, then soared 2686.84% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $510235.0 in 2022, then sank by 73.52% to $135099.0 in 2023, then soared by 1703.77% to $2.4 million in 2024, then declined by 7.6% to $2.3 million in 2025, then plunged by 56.99% to $968455.0 in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $968455.0, $2.3 million, and $1.2 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.46 Bn | 623.70 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 440.11 Bn | 433.54 Bn | 12.70 Bn | 106.45 Bn |
| 3 | Merck | 365.04 Bn | 357.90 Bn | 12.21 Bn | 16.16 Bn |
| 4 | Novartis Ag | 266.82 Bn | 259.13 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | 100.86 Bn |
| 6 | Sanofi | 52.47 Bn | 45.09 Bn | 10.79 Bn | 32.04 Bn |
| 7 | Revolution Medicines | 44.26 Bn | 44.26 Bn | - | 1.53 Bn |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | 1.40 Bn |
| 9 | United Therapeutics | 21.46 Bn | 18.80 Bn | 683.80 Mn | 607.80 Mn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | 968,455.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 968,455.00 |
| Dec 31, 2025 | 2.25 Mn |
| Sep 30, 2025 | 1.16 Mn |
| Mar 31, 2025 | 923,698.00 |
| Dec 31, 2024 | 2.44 Mn |
| Mar 31, 2024 | 33,145.00 |
| Dec 31, 2023 | 135,099.00 |
| Sep 30, 2023 | 234,160.00 |
| Jun 30, 2023 | 331,066.00 |
| Mar 31, 2023 | 422,802.00 |
| Dec 31, 2022 | 510,235.00 |
| Sep 30, 2022 | 604,142.00 |
| Dec 31, 2021 | 866,037.00 |